Login to Your Account



Immunocore’s T-Cell Cancer Vaccine Moves into Phase IIa

By Nuala Moran
Staff Writer

Wednesday, October 30, 2013
LONDON – Immunocore Ltd. has opened a Phase IIa trial of its T-cell cancer vaccine, IMGgp100, after demonstrating immune responses and evidence of tumor shrinkage in some of the 31 patients with late-stage melanoma who took part in the Phase I single-dose study.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription